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学 位 論 文 の 内 容 の 要 旨 
 
包 品杰   印 
（学位論文のタイトル） 
High STMN1 expression is associated with cancer progression and chemo-sensitivity 
in lung squamous cell carcinoma 
（肺扁平上皮癌における STMN1 の高発現は予後不良と抗癌剤耐性に関連する） 
1) Background and purpose 
Stathmin1 (STMN1) is known to regulate the dynamics of the microtubules, cell cycle 
progress and chemo-resistance against taxane agents. The high expression was reported in 
several human cancers and involved in cancer proliferation, chemo-resistance and poor 
prognosis. However, few studies investigated the significance of STMN1 in lung squamous 
cell carcinoma (LSCC). In this study, we aimed to examine the expression and function 
of STMN1 in LSCC. 
2) Materials and method  
STMN1 expression was examined by immunohistochemistry using FFPE tissue sections 
from 186 LSCC patients. All patients were classified in to discovery cohort whose sample 
obtained from General Surgical Science and validation cohort whose samples obtained from 
Thoracic Visceral Organ Surgery. STMN1 suppression analysis was performed 
for STMN1 siRNA transfected LSCC cell lines EBC1 and H520 to determine the change of 
proliferating, invasive, and paclitaxel-sensitivity. 
3) Results 
The cytoplasmic STMN1 expression in LSCC was higher than that of normal tissues. High 
STMN1 expression group (n=114) was significantly associated with vascular invasion and 
poor prognosis compared to the low group (n=72). In addition, the proliferating and 
invasive abilities were decreased and the apoptosis ability and paclitaxel-sensitivity were 
increased in STMN1 suppressed LSCC cells compared with the control cells.  
4) Discussion 
In this study, we demonstrated that high expression of STMN1 was associated with cancer 
progression and poor prognosis in LSCC patients. Consist with clinical out come, in vitro 
silencing of STMN1 using siRNA inhibited the invasion and proliferation of LSCC cell 
lines compared to control cells. 
5) Conclusion 
STMN1 could be a predictor for poor prognosis and potential therapeutic target in 
LSCC. In the further studies, we want to clarify the possibility of STMN1 as a taxane 
sensitivity marker and blood biomarker in clinical LSCC patients who treated with taxane 
agents.  
 
